Ketamine Infusion for Treatment-resistant Major Depressive Disorder
NCT01582945
Completed
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD). This is... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Depression Clinical and Research Program - MGH, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
NCT01667926
Completed
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Depression Clinical and Reseach Program - MGH, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
NCT01260649
Terminated
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in memory. It would be a major advance in treatment if ECT could work faster with fewer treatments and result in decrease incidence of memory problems. Ketamine is an excellent candidate for augmentation of ECT because of its acute effects on depression, its short half-life... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Lidocaine and Ketamine in Abdominal Surgery
NCT00721110
Terminated
This study is being done to determine if combined infusions of lidocaine and ketamine is better than a lidocaine or ketamine infusion alone, or to placebo in improving recovery after abdominal hysterectomy. Participants will be randomized into one of four groups. Evaluations will be done through walking tests, pain and fatigue questionnaires and blood tests.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2017
Locations: Cleveland Clinic/Hillcrest Hospital, Mayfield Heights, Ohio
Conditions: Abdominal Hysterectomy (& Wertheim)
Register for Updates
Treatment Study of Bipolar Depression
NCT00947791
Terminated
The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
04/11/2017
Locations: Mount Sinai School of Medicine, New York, New York
Conditions: Bipolar Disorder
Register for Updates
Treatment of Suicidal Ideation With Intravenous Ketamine Infusion
NCT01887990
Completed
This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/07/2017
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Depression, Suicidal Ideation
Register for Updates
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
NCT02234011
Terminated
This study is being done to learn whether administration of intranasal (inhaled through the nose) ketamine reduces symptoms of obsessive-compulsive disorder (OCD). Ketamine has been approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent (a medicine to reduce pain during surgery and other procedures) but ketamine has not been approved by the FDA as a treatment for OCD. The investigators believe that ketamine may be effective in reducing symptoms of OCD due to its ability... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/05/2017
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
NCT02206776
Terminated
Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3 months), and even then they usually only partially reduce OCD symptoms. The present study, will test if intranasal ketamine is feasible to use and can reduce OCD symptoms significantly more than a comparison medication called midazo... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/30/2017
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Obsessive-Compulsive Disorder
Register for Updates
IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D
NCT02635282
Completed
The general objective of this study is to determine whether intranasal ketamine should be incorporated into formulary as an option to treat pain during minor procedures in the pediatric emergency department.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
03/23/2017
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Abscess, Pain
Register for Updates
Anesthesia and Functional Connectivity: An Analysis of fMRI Changes
NCT02196259
Terminated
Functional connectivity is defined as a correlation in neural activity between distinct regions of the brain. Several recent studies have demonstrated areas of low-frequency functional connectivity inherent to brain tissue at rest. These oscillations can be measured using functional magnetic resonance imaging (fMRI) and appear to be synchronized between related areas of the brain. To date, no investigators have examined the effects of low-dose anesthesia on functional connectivity. This study w... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/21/2017
Locations: University of Michigan - fMRI Laboratory, Ann Arbor, Michigan
Conditions: Changes in Brain Network Connectivity
Register for Updates
Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
NCT02958566
Unknown
The General Objective of this study is to investigate the cost and efficacy of treating patients undergoing colorectal surgical resections with an opioid limited pain control regimen as part of an Enhanced Recovery After Surgery (ERAS) Protocol. This group will be compared to a traditional opioid based pain control regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2017
Locations: Uicomp, Peoria, Illinois
Conditions: Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Register for Updates
Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder
NCT01504659
Terminated
The investigators plan to evaluate the efficacy and safety of intranasal Ketalar (ketamine hydrochloride) in the treatment of primary symptom manifestations of pediatric bipolar disorder; Fear of Harm (FOH) phenotype. This phenotype represents those children who are most resistant to traditional treatments and suffer repeated hospitalizations. Primary symptoms include fearfulness, aggression secondary to threat, mood and/or arousal instability, and psychosis. In addition to evaluation of efficac... Read More
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
03/14/2017
Locations: Individual homes of subjects, Not Predetermined, Connecticut +3 locations
Conditions: Bipolar Disorder
Register for Updates